The recent surge in funding into niche pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." https://amberjazs639537.blogsumer.com/39128078/high-stakeholder-pharma-the-hazardous-bet